Company intelligence / Profile preview

Xaira Therapeutics

Brisbane, California, USAxaira.com ↗

Ownership: Private
Employees: ~86
Development stage: Preclinical

Overview

Xaira Therapeutics launched in April 2024 with over $1 billion in committed capital to pioneer the use of artificial intelligence across all stages of drug discovery and development. The company leverages advanced generative AI models—originating from the Institute for Protein Design—to create novel small molecules, proteins, and antibodies targeting challenging disease biology. While specific clinical results are not yet available due to the company's early stage, several preclinical candidates are reportedly advancing toward first-in-human studies.

Therapeutic areas: OncologyOther
Modalities: Small moleculesProtein therapeutics (including de novo designed proteins and antibodies)Potentially other biologics (company describes "multiple modalities")
Industry: Biotech

Beyond the preview

Go deeper on Xaira Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xaira Therapeutics.

Explore the full profile